Theon Pharmaceuticals LTD.

What Theon Pharmaceuticals LTD. does

Theon Pharmaceuticals Ltd. is an India-based, privately held Contract Development and Manufacturing Organization (CDMO) headquartered in Panchkula, Haryana, founded in 2005 (with firmographic records referencing 1997) and operating four manufacturing blocks across Baddi/Nalagarh (Himachal Pradesh) and Derabassi (Punjab), plus a planned Advanced R&D Center in Mohali. The company manufactures oral solid dosage forms (tablets, capsules, dry syrups, ointments, sachets), beta-lactam antibiotics and potassium clavulanate combinations, cephalosporins (OSD and dry syrups), dry powder injectables, and — following an October 2024 launch — sterile injectables and ophthalmic formulations, with annual capacity of 2,000 million tablets and 120 million vials/ampoules. Its differentiated offerings include India's first DCGI-approved Linagliptin + Dapagliflozin + Metformin Hydrochloride SR triple-combination Type II diabetes drug backed by Phase III clinical studies.

Theon's commercial model is B2B contract manufacturing under quote-based pricing, sold through direct enterprise field sales to pharmaceutical companies, with 14 of the top 15 Indian branded generic companies (Sun Pharma, Lupin, Mankind, Alembic, Torrent, Zydus, Alkem, Aristo) among its named customers. Distribution extends to hospitals, clinics, government health programs (Jan Aarogya Kendra under the Government of India, Ministry of Health Sri Lanka), and regulated international markets across Africa, Southeast Asia, CIS, Latin America, the Caribbean, and Asia Pacific, with product registrations in 23+ countries. Compliance is anchored by WHO-GMP, EU-GMP, ISO 9001:2015, NABL, and PIC/S-aligned certifications, plus DCGI permission for proprietary combinations and a DSIR-approved in-house R&D Centre. The company is led by Managing Director Amit Bansal under founder/owner Mukesh Bansal, is privately held with no disclosed institutional investors, and is expanding capacity into liquid and lyophilized injectables and an Advanced R&D Center for a planned 2026 launch.

Name

Theon Pharmaceuticals LTD.

Legal name

Theon Pharmaceuticals Ltd.

Website

https://theonpharma.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Theon Pharmaceuticals Ltd. is an India-based, privately held CDMO that manufactures oral solids, beta-lactams, cephalosporins, dry powder injectables, and sterile injectables/ophthalmics for top Indian branded generic companies, government health programs, and 30+ regulated international markets.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Pharmaceutical contract manufacturing
• Contract development manufacturing
• Generic drug manufacturing
• Cephalosporin antibiotics
• Dry powder injectables

Headquarters

HQ city

Haryana

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Pharmaceutical Manufacturing: Theon Pharmaceuticals operates as a CDMO (Contract Development and Manufacturing Organization) providing pharmaceutical manufacturing services to other pharmaceutical companies. The company manufactures products on behalf of clients including tablets, capsules, dry syrups, dry powder injectables, and ophthalmic formulations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Theon Pharmaceuticals operates as a Contract Development and Manufacturing Organization (CDMO) producing oral solid dosage forms (general, beta-lactam antibiotics, cephalosporins in tablets/capsules/dry syrups), sterile dry powder injectables (cephalosporins, penicillins, carbapenems, potassium clavulanate combinations) and injectable/ophthalmic formulations. Manufacturing is delivered to pharmaceutical companies, hospitals, clinics, pharmacies and government health programmes under WHO-GMP, EU-GMP and PIC/S certified facilities with DSIR-approved R&D.

Product overview

Theon Pharmaceuticals is a Contract Development and Manufacturing Organization (CDMO) offering comprehensive pharmaceutical manufacturing services. The company operates multiple production blocks (Blocks A through D) providing oral solid dosage forms (General products, Beta Lactam antibiotics, Cephalosporins in tablets/capsules/dry syrups) and sterile injectable products (Dry Powder Injectables, Cephalosporin Injectables). The portfolio includes specialized offerings like India\'s first DCGI-approved combination diabetes drugs. Manufacturing is conducted across multiple WHO-GMP and EU-GMP compliant facilities with dedicated R&D capabilities for new formulation development.

Differentiator

Problem solved

Functional benefit

Products and services

• General Pharmaceutical Products Oral solid dosage forms including tablets, capsules, dry syrups, ointments and sachets manufactured in a dedicated General block under WHO-GMP and EU-GMP compliance for Indian and international pharmaceutical clients.
• Beta-Lactam Antibiotic Products Penicillin-based antibiotics and combinations including potassium clavulanate manufactured in a segregated Beta-Lactam block to prevent cross-contamination, supplying Indian and global pharmaceutical companies.
• Cephalosporin Products Cephalosporin antibiotics in oral solid dosage forms (tablets and capsules) and dry syrups, produced in dedicated manufacturing blocks using Cadmach Compression Machines and auto coaters for pharmaceutical clients.
• Dry Powder Injectables Sterile dry powder injectable medications including cephalosporins, penicillins, carbapenems and potassium clavulanate combinations, manufactured in Grade A/Class 100 cleanrooms with automatic vial washing, sterilizing and filling systems for global pharmaceutical partners.
• Linagliptin + Dapagliflozin Tablet DCGI-approved Type II diabetes combination drug pairing Linagliptin 5mg with Dapagliflozin 10mg, supported by Phase III clinical studies conducted by an internationally approved CRO, sold as a finished formulation.
• Linagliptin + Dapagliflozin + Metformin Hydrochloride SR Tablet India's first DCGI-approved triple-combination Type II diabetes tablet combining Linagliptin, Dapagliflozin and sustained-release Metformin, manufactured exclusively by Theon with Phase III clinical success and commercialised at scale.
• Injectable and Ophthalmic Formulations Manufacturing (Derabassi Facility) Sterile injectable and ophthalmic formulation manufacturing services delivered from the new Derabassi facility, catering to regulated markets with an annual capacity of 120 million vials and ampoules.

Quantifiable outcome

• Ranked among Top 10 leading injectable companies in India
• +3 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core.

• PPB KenyacoreOthersPharmaceutical regulatory approval from PPB Kenya for product registration and market access in Kenya.
• TMDA TanzaniacoreOthersPharmaceutical regulatory approval from Tanzania Medicines and Medical Devices Authority for market access.
• EFDA EthiopiacoreOthersEthiopian Food and Drug Authority approval for pharmaceutical product registration.
• NAFDAC NigeriacoreOthersNational Agency for Food and Drug Administration and Control Nigeria certification.
• FDA PhilippinescoreOthersPhilippine Food and Drug Administration approval for pharmaceutical manufacturing and product registration.
• Ministry of Health Sri LankacoreStrategic or Co-development PartnerPartnership with Sri Lankan Ministry of Health to develop and manufacture high-quality pharmaceutical products meeting local healthcare needs while adhering to international quality standards.
• Jan Aarogya Kendra (Government of India)coreStrategic or Co-development PartnerCollaboration under Government of India's Jan Aarogya Kendras initiative to provide affordable and accessible healthcare services to rural areas. Theon manufactures pharmaceutical products meeting unique needs of rural communities at affordable pricing.
• Government Regulatory Bodies (23 countries)coreOthersProduct registrations and approvals from regulatory bodies including FDA Ghana, NDA Uganda, DPM Ivory Coast, MoH Myanmar, MoH Sri Lanka, DAV Vietnam, MoH Cambodia, MoH Iraq, MoH Yemen, MoH Venezuela, MoH Uzbekistan, MoH Afghanistan, MoH Swaziland, MCAZ Zimbabwe, NDSO Lesotho, MINSA Nicaragua, and regulatory bodies in Ecuador, Cuba, Dominican Republic.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Alkem Laboratories: One of India's top 10 pharma companies and a disclosed customer of Theon, with strong anti-infectives portfolio. Comparable product mix and a leading Indian generic brand manufacturer.
• Aurobindo Pharma: One of India's largest generic pharmaceutical manufacturers with API and finished dosage capabilities including injectables. Larger incumbent competing in similar therapeutic categories and exporting globally.
• Ipca Laboratories: Indian pharmaceutical company with API and finished dosage manufacturing across multiple therapeutic areas. Larger incumbent operating in similar generic pharmaceutical manufacturing categories including anti-infectives.
• Granules India: Indian pharmaceutical manufacturer producing finished dosages and APIs with high-volume, low-cost model. Comparable in scale economics and B2B manufacturing approach to oral solids and injectables.
• Emcure Pharmaceuticals: Indian pharma manufacturer with strong presence in oral solids, injectables, and biotech. Comparable in domestic market leadership, exports, and recent capacity expansions.

Direct peers

• Jubilant Pharmova: Indian pharma and CDMO business with sterile injectables, APIs, and radiopharma. Comparable CDMO model serving regulated markets with injectable capacity investments.
• Syngene International: Leading Indian contract research, development and manufacturing organization (CRDMO) offering integrated services. Comparable contract services model with India-based manufacturing and development for global pharma.
• Piramal Pharma Solutions: Global CDMO arm of Piramal Pharma offering sterile injectables, oral solids, and development services. Directly comparable CDMO with injectable manufacturing capability serving multinational pharma clients.
• Akums Drugs & Pharmaceuticals: India's largest contract manufacturer of pharmaceuticals offering oral solids, injectables, and various dosage forms. Most directly comparable CDMO in India by manufacturing breadth and customer model serving Indian branded generic companies.
• Suven Pharmaceuticals: Indian CDMO focused on contract development and manufacturing of API and intermediates for global pharma. Comparable business model serving regulated markets with strong R&D and quality infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/THEONPHARMA
• YouTubeyoutube.com/watch?v=hA01pSBPgr4
• Facebookfacebook.com/theon.pharmaceuticals
• LinkedInlinkedin.com/company/theon-pharmaceuticals-ltd.

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theon Pharmaceuticals LTD.